
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
Key Takeaways
- In treatment-naive, RAS-mutant metastatic PDAC, daraxonrasib 200 mg plus GnP achieved 60.7% confirmed ORR, including 8.2% complete responses, with 90.2% disease control.
- Durability metrics were notable, with median PFS 12.8 months, median response duration 11.1 months, and a 12-month OS rate of 76.6% at 18.3 months follow-up.
Updated RMC-GI-102 data show 60.7% ORR and 12.8-month median PFS with daraxonrasib plus GnP in first-line metastatic PDAC.
The combination of daraxonrasib (Rasonque) and gemcitabine and nab-paclitaxel (GnP) led to durable responses and a median progression-free survival (PFS) of more than 1 year as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC), according to updated phase 1/2 data presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA).1,2
In the first-line cohort of the RMC-GI-102 study (NCT06445062), 61 patients treated with a 200-mg dose of daraxonrasib plus GnP had a confirmed objective response rate (ORR) of 60.7% (95% CI, 47.3%-72.9%), including complete responses in 8.2%, at a median follow-up of 18.3 months. Median PFS was 12.8 months (95% CI, 10.8-18.4), and the 12-month overall survival (OS) rate was 76.6% (95% CI, 63.7%-85.4%).1-3
“With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median [PFS] exceeding [1] year,” said Wungki Park, MD, MS, medical oncologist at the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center and presenter of the data, in a news release.1
Updated Efficacy of Daraxonrasib Plus GnP
Disease control was achieved in 90.2% of patients (95% CI, 79.8%-96.3%) as of the September 28, 2026, cutoff, and responses lasted a median of 11.1 months (95% CI, 7.6-18.4). Park presented the findings as a late-breaking oral abstract (8LBA) in Barcelona, Spain.1
The update extends an analysis reported in April at the 2026 American Association for Cancer Research (AACR) Annual Meeting.1 That earlier analysis included 40 patients with RAS-mutant disease at a median follow-up of 9.7 months, with an ORR of 58% (95% CI, 41%-73%) and a 6-month PFS rate of 84%.4 The RMC-GI-102 cohort enrolled patients with treatment-naive, RAS-mutant metastatic PDAC.3
Safety Profile of Daraxonrasib Plus GnP
The safety profile was reported to be consistent with the known profiles of daraxonrasib and GnP.1,2 In the AACR 2026 analysis, grade 3 or higher treatment-related AEs (TRAEs) occurred in 73% of patients and serious TRAEs in 28%, with no grade 5 TRAEs. Rash (90%), diarrhea (75%), fatigue (70%), and nausea (68%) were the most common TRAEs, and grade 3 or higher anemia occurred in 33%. Daraxonrasib dose reductions were required in 35% of patients, and 2 patients discontinued daraxonrasib because of TRAEs.4
Regulatory Status and Phase 3 Development of Daraxonrasib
The FDA granted
The randomized phase 3 RASolute 303 trial (NCT07491445) is comparing daraxonrasib monotherapy and daraxonrasib plus GnP with GnP alone in patients with previously untreated metastatic PDAC, regardless of RAS genotype.1-3
The findings add to the rationale for moving RAS(ON) inhibition earlier in metastatic PDAC, where GnP is a standard first-line chemotherapy backbone. With daraxonrasib already approved as monotherapy in this disease, the phase 3 RASolute 303 trial will test whether adding it to GnP, or giving it alone, improves outcomes vs GnP in the first-line setting.
“Taken together, these findings provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option,” Park said.1
REFERENCES
1. Revolution Medicines presents updated phase 1/2 data for RASONQUE® (daraxonrasib) plus chemotherapy in first-line metastatic pancreatic cancer at ENA 2026. News release. Revolution Medicines. November 19, 2026. Accessed November 20, 2026. https://www.revmed.com/media/news/13771/revolution-medicines-presents-updated-phase-1-2-data-for-rasonque-daraxonrasib-plus-chemotherapy-in-first-line-metastatic-pancreatic-cancer-at-ena-2026
2. Park W et al. Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC). Presented at: 38th EORTC-NCI-AACR Symposium 2026; November 18–20, 2026; Barcelona, Spain. Abstract 8 LBA.
3. Revolution Medicines announces U.S. FDA breakthrough therapy designation for Rasonque (daraxonrasib) in combination with chemotherapy for first line metastatic pancreatic cancer. News release. Revolution Medicines. September 14, 2026. Accessed November 20, 2026. https://www.biospace.com/press-releases/revolution-medicines-announces-u-s-fda-breakthrough-therapy-designation-for-rasonque-daraxonrasib-in-combination-with-chemotherapy-for-first-line-metastatic-pancreatic-cancer
4. Wolpin BM, Musher BL, Manji GA, et al. Daraxonrasib plus chemotherapy (CT) as first line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC). Presented at: 2026 AACR Annual Meeting; April 17–22, 2026; San Diego, CA. Abstract LB407.
Related to this article








